TipRanks
Advertisement
Advertisement

DE:EII Stock Latest News

Eisai Earnings Call Highlights LEQEMBI-Driven Surge
Company AnnouncementsEisai Earnings Call Highlights LEQEMBI-Driven Surge
2M ago
Eisai Co (ESALF) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Eisai Co (ESALF) Q1 Earnings Cheat Sheet
2M ago
Eisai Earnings Call Highlights LEQEMBI-Led Growth
PremiumCompany Announcements
Eisai Earnings Call Highlights LEQEMBI-Led Growth
5M ago
Eisai Co (ESALF) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Eisai Co (ESALF) Q4 Earnings Cheat Sheet
5M ago
ESALF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ESALF Earnings this Week: How Will it Perform?
8M ago
Is ESALF a Buy, Before Earnings?
PremiumPre-EarningsIs ESALF a Buy, Before Earnings?
1y ago
Eisai Co’s Strategic Initiatives and Growth Justify Buy Rating Despite Leqembi Guidance Concerns
Premium
Ratings
Eisai Co’s Strategic Initiatives and Growth Justify Buy Rating Despite Leqembi Guidance Concerns
1y ago
Eisai Co. Surpasses FY 2024 Expectations Amid Challenges
Premium
Company Announcements
Eisai Co. Surpasses FY 2024 Expectations Amid Challenges
1y ago
Eisai Co. Reports Cautious Optimism Amid Q3 Growth
PremiumCompany Announcements
Eisai Co. Reports Cautious Optimism Amid Q3 Growth
2y ago
ESALF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ESALF Earnings this Week: How Will it Perform?
2y ago
Eisai Co (ESALF) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Eisai Co (ESALF) Q2 Earnings Cheat Sheet
2y ago
ESALF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ESALF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2y ago
Japanese Stocks: Eisai Shares Plummet as EU Rejects Alzheimer’s Drug
PremiumGlobal MarketsJapanese Stocks: Eisai Shares Plummet as EU Rejects Alzheimer’s Drug
2y ago
BIIB
Eisai, Biogen say lecanemab received Priority Review status in Japan
Premium
The Fly
Eisai, Biogen say lecanemab received Priority Review status in Japan
4y ago
BIIB
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
Premium
The Fly
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
4y ago
BIIB
Catalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII
PremiumThe FlyCatalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII
4y ago
CPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >